REGULATORY

• LDP Urges Action on Drug Supply Risks Linked to Reliance on Specific Countries
  March 16, 2026

• 874 Defects or Health Damages Reported for Regenerative Medical Products in 1H FY2025
  March 13, 2026

• Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
  March 12, 2026

• GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
  March 12, 2026

• Truqap Price Cut Set at 10.7% from June under CEA Scheme
  March 12, 2026

• Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
  March 12, 2026

• Council Floats 9.6% Growth Goal for Global Patented Drug Sales by Japan Pharma
  March 11, 2026

• MHLW Approves Towa Generics for Revolade, Vimpat
  March 11, 2026

• Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
  March 10, 2026

• Japan Approves MSD’s HIV Combo Idvynso
  March 9, 2026

• MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
  March 9, 2026

• MHLW Orders Label Revisions for Cancer Drugs, Anticoagulant over Bleeding Risk
  March 9, 2026

• Japan Health Minister Lauds Approval of iPSC-Based Therapies
  March 9, 2026

• Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
  March 6, 2026

• Forxiga Slapped with 36% Price Cut on PMP Return in FY2026 Revision
  March 6, 2026

• Japan Panel Clears Joenja, Dojolvi, Bayer MRI Contrast Agent
  March 6, 2026

• Japan's Revised Drug Distribution Guidelines Take Effect
  March 6, 2026

• Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
  March 5, 2026

• Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
  March 5, 2026

• MHLW Clarifies Use of Real-World Data in Drug Applications
  March 5, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »